ArticleMedical oncology (Northwood, London, England)2011
Medullary carcinoma of the breast: a population-based perspective.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Breast cancer survival prediction using machine learning and multimodal data for personalized care plan.BMC cancer · 2026Article
- Survival outcomes by molecular subtypes based on receptor status in medullary breast carcinoma: a SEER database analysis.Translational cancer research · 2026Article
- A population-based analysis of a risk stratification system for predicting radiotherapy benefits in invasive breast carcinoma of no special type with medullary pattern.European journal of medical research · 2025Article
- Clinicopathological observation and prognostic factors of invasive breast cancer with medullary in Xinjiang.BMC medical informatics and decision making · 2025Article
- Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024Review
- Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations.Current breast cancer reports · 2024Article
- A risk stratification model to predict chemotherapy benefit in medullary carcinoma of the breast: a population-based SEER database.Scientific reports · 2023Article
- Recognizing invasive breast carcinoma of no special type with medullary pattern.Radiology case reports · 2023Article
- Medullary breast cancer is a predominantly triple-negative breast cancer - histopathological analysis and comparison with invasive ductal breast cancer.Archives of medical science : AMS · 2022Article
- Invasive Breast Carcinoma of No Special Type with Medullary Pattern: Morphological and Immunohistochemical Features.Turk patoloji dergisi · 2022Article
- Hormone Receptor Status May Impact the Survival Benefit Between Medullary Breast Carcinoma and Atypical Medullary Carcinoma of the Breast: A Population-Based Study.Frontiers in oncology · 2021Article
- Competing Risk Analyses of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma.Scientific reports · 2020Article
- Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study.Iranian journal of medical sciences · 2018Article
- Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.Saudi medical journal · 2017Article
- Article
- Article
- Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases.PloS one · 2014Article
- Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma.Journal of breast cancer · 2013Article
- Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.World journal of surgical oncology · 2013Article
- An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.International journal of clinical and experimental pathology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Prognostic factors specific to medullary carcinoma of the breast (MCB) are unknown. Our objective was to identify patient and tumor factors predictive of overall survival (OS) in a large cohort of MCB patients. The Surveillance, Epidemiology, and End Results database was used to identify patients with MCB diagnosed from 1988 to 2004. Patient, tumor, and treatment factors were compared by univariate analysis via the Kaplan–Meier method and survival differences detected using the log-rank test. A multivariate Cox proportional hazards model controlled for patient age, race, type of surgery, radiotherapy, tumor size, number of lymph node metastases (LNM), lymph node yield (LNY), estrogen receptor (ER) and progesterone receptor (PR) status, and extent of disease. On univariate analysis of 3,348 patients, factors influencing OS included age, race, tumor size, ER status, type of surgery, radiotherapy, LNM, LNY, and extent of disease (P<0.001). On multivariate analysis, advancing age (P<0.001), black race (P<0.001), regional metastases (P<0.001), distant metastases (P<0.001), increasing tumor size (P<0.001), ER positivity (P=0.003), and increasing LNM (P<0.001) were associated with decreased OS. An OS benefit was seen in PR-positive patients (P=0.002) and in those with increasing LNY (P<0.001). Even among node-negative patients, increasing LNY was associated with improved OS (P<0.001). Tumor size, LNM, regional and distant metastases, PR status, age, and race are important prognostic factors in MCB. ER positivity was associated with decreased OS, which may reflect inaccuracy in diagnosing MCB or a significant biologic variant. The improved OS seen with increasing LNY in node-negative patients suggests MCB may be currently understaged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.